Silvia

List of Publications by Citations

Source: https://exaly.com/author-pdf/7105165/silvia-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47 895 15 29 g-index

47 1,059 3.8 3.38 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
47	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. <i>Endocrine-Related Cancer</i> , 2010 , 17, 445-53	5.7	106
46	Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer, 2008 , 15, 1043-53	5.7	106
45	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2012 , 166, 451-8	6.5	104
44	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1721-6	3.2	82
43	In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2012 , 74, 201-210		70
42	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 59, 109-16	3.5	53
41	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 293-300	1.9	29
40	A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. <i>Journal of Chromatographic Science</i> , 2011 , 49, 753-7	1.4	29
39	Practical treatment using mitotane for adrenocortical carcinoma. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014 , 21, 159-65	4	25
38	A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 893-894, 127-33	3.2	24
37	Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009 , 116, 29-36	5.1	24
36	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 197-203	3.8	23
35	Intense physical exercise increases systemic 11beta-hydroxysteroid dehydrogenase type 1 activity in healthy adult subjects. <i>European Journal of Applied Physiology</i> , 2010 , 108, 681-7	3.4	21
34	Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2017 , 177, 361-367	6.5	19
33	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. <i>Molecular and Cellular Endocrinology</i> , 2015 , 401, 105-10	4.4	18
32	The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2008 , 159, 569-76	6.5	15
31	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020 , 12,	6.6	14

30	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016 , 17, 561-72	2.6	13
29	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 1083-1088	3	13
28	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017 , 5,	4.8	12
27	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017 , 18, 539-554	2.6	10
26	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
25	Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 410-2	3.2	9
24	Deferasirox pharmacokinetic and toxicity correlation in Ethalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 1417-1421	4.8	9
23	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1524-1530	4.8	6
22	Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns. <i>Molecular and Cellular Biochemistry</i> , 2017 , 434, 51-60	4.2	5
21	Quantification of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia: Comparison Between HPLCDV and LCMS/MS. <i>International Journal of Peptide Research and Therapeutics</i> , 2013 , 19, 109-116	2.1	5
20	CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. <i>PLoS ONE</i> , 2018 , 13, e0196931	3.7	5
19	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. <i>Pharmacological Research</i> , 2021 , 173, 105848	10.2	5
18	Deferasirox pharmacokinetic evaluation in Ethalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 525-528	4.8	4
17	Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats. <i>Psychoneuroendocrinology</i> , 2012 , 37, 1234-47	5	4
16	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 417-427	3.5	4
15	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 17-22	1.9	4
14	Clinical relevance of deferasirox trough levels in Ethalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 213-216	3	3
13	A current perspective on treatment of adrenocortical carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 911-921	1.1	2

12	Short QT syndrome in infancy. Therapeutic drug monitoring of hydroquinidine in a newborn infant. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 982-4	3.8	2
11	Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. <i>Life</i> , 2021 , 11,	3	2
10	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous Ethalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 84, 1510-1512	7.5	2
9	Effect of Gender and Agelon Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020 , 45, 405-412	2.7	1
8	Correlated quantification using microbiological and electrochemical assays for roxithromycin determination in biological and pharmaceutical samples. <i>Talanta</i> , 2020 , 211, 120703	6.2	1
7	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 199-206	1.9	1
6	The Influence of Sex, Gender, and Age on COVID-19 Data in the Piedmont Region (Northwest Italy): The Virus Prefers Men. <i>Life</i> , 2022 , 12, 643	3	1
5	Gender-specific side effects of chemotherapy in pancreatic cancer patients <i>Canadian Journal of Physiology and Pharmacology</i> , 2021 , 1-7	2.4	O
4	Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?. <i>European Journal of Clinical Pharmacology</i> , 2022 , 1	2.8	O
3	Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring. <i>Blood</i> , 2019 , 134, 3547-3547	2.2	
2	Mitotane 2009 , 369-381		
1	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022 , 15, 630	5.2	